Long-term follow-up of intravesical abobotulinumtoxinA (Dysport<sup>®</sup>) injections in women with idiopathic detrusor overactivity

doi:10.1016/j.ajur.2022.02.012

Asian Journal of Urology, 2024, 11 (1): 93-98 doi: 10.1016/j.ajur.2022.02.012

Original Articles

Long-term follow-up of intravesical abobotulinumtoxinA (Dysport^®) injections in women with idiopathic detrusor overactivity

Mohammad Sajjad Rahnama'i^a,Amin Bagheri^b,Elham Jahantabi^c,Hanieh Salehi-Pourmehr^b,Hadi Mostafaei^d,Brigitte Schurch^e,Aida Javan Balegh Marand^f,Sakineh Hajebrahimi^b,*(

)

^aDepartment of Urology, St. Elisabeth-Tweesteden Hospital Tilburg, the Netherlands
^bResearch Center for Evidence-based Medicine, Iranian EBM Centre: A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz University of Medical Sciences, Tabriz, Iran
^cUrology Department, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
^dDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
^eService de Neuroréhabilitation, CHUV, Lausanne, Switzerland
^fSociety of Urological Research and Education (SURE), Heerlen, the Netherlands

Abstract
Related Citation (6)

Download:

HTML

PDF (1023KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective: Only a few numbers of studies have been published on the use of abobotulinumtoxinA (Dysport^®) in idiopathic detrusor overactivity (IDO). This study reported the long-term follow-up of women with IDO who were treated with intravesical Dysport^® injections.

Methods: Two hundred and thirty-six patients with IDO who had failed first-line conservative and antimuscarinic therapy received 500-900 units of Dysport^® between April 2014 and July 2015. All patients were followed up for 5 years after their initial injection and interviewed on the phone.

Results: A total of 236 women with IDO aged from 18 years to 84 years (mean±standard deviation: 49.6±15.9 years) were included in our study. The median follow-up time for patients was 36.5 (range: 10-70) months, and the median recovery time after injection was 18.5 (range: 0-70) months. A total of 83 (35.2%) patients stated that they had subjective improvement of their symptoms whereas 84 (35.6%) patients did not report any improvement in symptoms. The initial International Consultation on Incontinence Questionnaire Overactive Bladder mean score was 6.9 (standard deviation 3.4). There was a positive association between the median recovery time and the components of the International Consultation on Incontinence Questionnaire Overactive Bladder questionnaire.

Conclusion: In a sub-population of overactive bladder patients with IDO who have failed first-line therapy, a single intravesical Dysport^® injection can resolve patient symptoms completely or reduce the symptoms to an acceptable level that can be controlled with antimuscarinics or re-injection on demands.

Key words： AbobotulinumtoxinA Dysport^® Intravesical Idiopathic Detrusor overactivity

Received: 05 May 2021 Available online: 20 January 2024

Corresponding Authors: *E-mail address: hajebrahimis@gmail.com (S. Hajebrahimi), ebrahimis@tbzmed.ac.ir (S. Hajebrahimi).

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Mohammad Sajjad Rahnama'i
	Amin Bagheri
	Elham Jahantabi
	Hanieh Salehi-Pourmehr
	Hadi Mostafaei
	Brigitte Schurch
	Aida Javan Balegh Marand
	Sakineh Hajebrahimi

TRENDMD:

Cite this article:

Mohammad Sajjad Rahnama'i,Amin Bagheri,Elham Jahantabi, et al. Long-term follow-up of intravesical abobotulinumtoxinA (Dysport^®) injections in women with idiopathic detrusor overactivity[J]. Asian Journal of Urology, 2024, 11(1): 93-98.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2022.02.012 OR http://www.ajurology.com/EN/Y2024/V11/I1/93

Clinical characteristics and ICIQ-OAB questionnaire scores for all patients (n=236).

The Kaplan-Meier survival curve of the follow-up period (n=236).

The Kaplan-Meier plot survival curve of the duration of recovery in patient (n=236).

Association between patient ICIQ-OAB scores and recovery with patient satisfaction (n=236).

Log rank test between ICIQ-OAB score and recovery duration (n=236). ICIQ-OAB, International Consultation on Incontinence Questionnaire Overactive Bladder.

[1]	Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20:327-36. doi: 10.1007/s00345-002-0301-4 pmid: 12811491
[2]	Sacco E, Tienforti D, D’Addessi A, Pinto F, Racioppi M, Totaro A, et al. Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol 2010; 2:11-24.
[3]	Hollingworth W, Campbell JD, Kowalski J, Ravelo A, Girod I, Briggs A, et al. Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. Qual Life Res 2010; 19: 323-31. doi: 10.1007/s11136-010-9590-z pmid: 20094804
[4]	Lee JS, Koo BI, Shin MJ, Chang JH, Kim SY, Ko HY. Differences in urodynamic variables for vesicoureteral reflux depending on the neurogenic bladder type. Ann Rehabil Med 2014; 38:347-52. doi: 10.5535/arm.2014.38.3.347 pmid: 25024958
[5]	Garely AD, Burrows LJ. Current pharmacotherapeutic strategies for overactive bladder. Expet Opin Pharmacother 2002; 3: 827-33.
[6]	Asimakopoulos AD, Cerruto MA, Del Popolo G, La Martina M, Artibani W, Carone R, et al. An overview on mixed action drugs for the treatment of overactive bladder and detrusor overactivity. Urol Int 2012; 89:259-69. doi: 10.1159/000339600 pmid: 22777274
[7]	Jundt K, Schreyer K, Friese K, Peschers U. Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet 2011; 284:663-6. doi: 10.1007/s00404-010-1720-x pmid: 21046135
[8]	Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000; 55:33-46. pmid: 10767450
[9]	Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48:5-26. pmid: 15885877
[10]	Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184: 2416-22. doi: 10.1016/j.juro.2010.08.021 pmid: 20952013
[11]	Jhang JF, Kuo HC. Novel applications of onabotulinumtoxinA in lower urinary tract dysfunction. Toxins 2018; 10:260. https://doi.org/10.3390/toxins10070260. doi: 10.3390/toxins10070260
[12]	Field M, Splevins A, Picaut P, Van der Schans M, Langenberg J, Noort D, et al. AbobotulinumtoxinA (Dysport®), onabotulinumtoxinA (Botox®), and incobotulinumtoxinA (Xeomin®) neurotoxin content and potential implications for duration of response in patients. Toxins 2018; 10:535. https://doi.org/10.3390/toxins10120535. doi: 10.3390/toxins10120535
[13]	Stoehrer M, Wolff A, Kramer G, Steiner R, Lm?chner-Ernst D, Leuth D, et al. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int 2009; 83: 379-85. doi: 10.1159/000251175 pmid: 19996642
[14]	Craciun M, Irwin PP. Outcomes for intravesical abobotulinumtoxinA (Dysport) treatment in the active management of overactive bladder symptoms-a prospective study. Urology 2019; 130:54-8. doi: S0090-4295(19)30375-9 pmid: 31029669
[15]	Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665. https://doi.org/10.1056/NEJM200003023420918. doi: 10.1056/NEJM200003023420918
[16]	Schurch B, Carda S. OnabotulinumtoxinA and multiple sclerosis. Ann Phys Rehabil Med 2014; 57:302-14. doi: S1877-0657(14)01723-0 pmid: 24953702
[17]	Marcelissen TA, Rahnama’i MS, Snijkers A, Schurch B, De Vries P. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol 2017; 35:307-11. doi: 10.1007/s00345-016-1862-y pmid: 27272312
[18]	Marcelissen TR, Brierley B, Schurch B, De Vries P. Treatment failure of botulinum toxin-A in patients with idiopathic overactive bladder: why do patients discontinue treatment? Nephro-Urol Mon 2017; 9:e46569. https://doi.org/10.5812/numonthly.46569.
[19]	Ragab M, Yang B, Guy P, Davies M. 10-year follow-up study on long-term intravesical botulinum toxin A injections efficacy for overactive bladder treatment. Eur Urol Suppl 2019; 18: e175-6. https://doi.org/10.1016/S1569-9056(19)30133-2. doi: 10.1016/S1569-9056(19)30133-2
[20]	Marion MH, Sheehy M, Sangla S, Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatr 1995; 59:102-3. doi: 10.1136/jnnp.59.1.102
[21]	Whurr R, Brookes G, Barnes C. Comparison of dosage effects between the American and British botulinum toxin A product in the treatment of spasmodic dysphonia. Mov Disord 1995 ;10. https://doi.org/10.1002/mds.870100331.
[22]	Kollewe K, Mohammadi B, Dengler R, Dressler D. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. J Neural Transm 2010; 177: 759-63.
[23]	Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, et al. A double-blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia. J Neurol 1998; 64:6-12.
[24]	Shin JH, Jeon C, Woo KI, Kim YD. Clinical comparability of Dysport and Botox in essential blepharospasm. J Korean Ophthalmol Soc 2009; 50:331-5. doi: 10.3341/jkos.2009.50.3.331
[25]	Wohlfarth K, Schwandt I, Wegner F, Jürgens T, Gelbrich G, Wagner A, et al. Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 2008; 255:1932-9. doi: 10.1007/s00415-008-0031-7 pmid: 18854916
[26]	Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009; 31:463-6. doi: 10.1179/174313209X405137 pmid: 19278576
[27]	Rystedt A, Nyholom D, Naver H. Clinical experience of dose conversion ratios between toxin products in the treatment of cervical dystonia. Clin Neuropharmacol 2012; 35:278-82. doi: 10.1097/WNF.0b013e3182711fc0 pmid: 23123690
[28]	Sampaio C, Ferreira JJ, Sim?es F, Rosas MJ, Magalh?es M, Correia AP, et al. Dysport: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and Botox, assuming a ratio of 4:1. Mov Disord 1997; 12:1013-8. doi: 10.1002/mds.v12:6
[29]	Nussgens Z. Comparison of two botulinum toxin preparations in the treatment of essential blepharospasm. Clin Exp Ophthalmol 1997; 235:197-9.
[30]	Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. Toxins 2016; 8:65. https://doi.org/10.3390/toxins8030065. doi: 10.3390/toxins8030065
[31]	Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox and Dysport: a double-blind, randomised, crossover study in cervical dystonia. J Neurol 2002; 72: 459-62.
[32]	Bentivoglio AR, Ialongo T, Bove F, de Nigris F, Fasano A. Retrospective evaluation of the dose equivalence of Botox and Dysport in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci 2012; 33:261-7. doi: 10.1007/s10072-011-0672-7 pmid: 21710123
[33]	Abeywickrama L, Arunkalaivanan A, Quinlan M. Repeated botulinum toxin type A (Dysport) injections for women with intractable detrusor overactivity: a prospective outcome study. Int Urogynecol J 2014; 25:601-5. doi: 10.1007/s00192-013-2228-2 pmid: 24132493
[34]	Irwin P, Somov P, Ekwueme K. Patient reported outcomes of abobotulinumtoxinA injection treatment for idiopathic detrusor overactivity: a pragmatic approach to management in secondary care. J Clin Urol 2013; 6:59-63.